Introduction

Cervical cancer is a health concern in India, but the way it is addressed in public discourse often relies on outdated statistics and fear-driven narratives. The oft-repeated claim that “1 in 53 women in India will develop cervical cancer in their lifetime” has been widely circulated in campaigns promoting HPV vaccination. This figure, however, originates from Globocan estimates nearly a decade old and fails to account for India’s unique mortality realities. In truth, many women do not live long enough to reach the age bracket where cervical cancer incidence peaks, making the actual lifetime risk significantly lower.

India’s age-standardized incidence rate (ASR) has declined from 22–23 per 100,000 in 2012–2014 to about 10 per 100,000 by 2022–2026. India’s Cervical Cancer Risk is Below Global Averages and is Declining Further in 2026. When adjusted for survival realities, the lifetime risk is closer to 1 in 100–140 women, not 1 in 53. Inflated statistics misrepresent the epidemiological situation, create unnecessary fear, and frame HPV vaccination as the only solution.

This approach undermines trust in public health and distracts from what is truly needed: sexual healthcare education combined with quick, precise, and safe treatments such as photodynamic therapy (PDT), frequency-based therapies, and metabolic approaches.

The focus must shift from fear-based vaccine promotion to empowering women with knowledge, preventive practices, and access to innovative treatments. Sexual healthcare education—covering safe practices, regular screening, and early detection—provides the foundation. Modern therapies like PDT, cryotherapy, cryoablation, and metabolic interventions offer effective, fertility-preserving options for those who develop HPV-related lesions. Together, education and advanced treatment form a comprehensive, patient-centered strategy that is safer, more transparent, and more empowering than relying on forced vaccination campaigns.

Refuting The “1 in 53” Claim

The “1 in 53” figure assumes women survive long enough to face the full lifetime risk of cervical cancer. In India, however, about 95% of women who might develop cervical cancer would already have died from other causes before reaching the peak risk age of 50–75. Current ASR has declined to about 10 per 100,000 by 2022–2026. Adjusted for survival realities, the lifetime risk is closer to 1 in 100–140 women. Inflated statistics misrepresent the epidemiological situation and undermine trust in public health messaging.

Cervical Cancer In Younger Women

Cervical cancer deaths among females aged 15–20 are extremely rare, with less than 1% of cases occurring in this group. Incidence rises only after age 25, and most fatalities occur between ages 30–50. WHO Globocan 2022 reported 127,526 new cervical cancer cases and 79,906 deaths in India, but almost none in women under 20. So prevention through education and screening remains critical.

The Polarized HPV Vaccine Debate

The HPV vaccine debate is deeply polarized. Global health authorities such as WHO, CDC, and EMA affirm vaccine safety and effectiveness, citing reductions in precancers and genital warts. Critics, however, highlight conflicts of interest, under-reporting of adverse events, and the dominance of pharmaceutical funding in research. Leadership in health organizations often comes from political or administrative backgrounds rather than medical expertise, fueling perceptions of bias. Thus, the controversy is not only about one vaccine but about governance, transparency, and trust in public health institutions.

PCR Testing And Viral Detection

Polymerase Chain Reaction (PCR), invented by Kary Mullis, revolutionized virology by enabling detection of minute viral fragments. For HPV, PCR-based DNA tests are more sensitive than Pap smears. However, PCR detects fragments, not active infection, and cannot distinguish between live virus and remnants. Despite limitations, PCR remains the global diagnostic standard, complemented by electron microscopy in specialized contexts. This must be changed now as growing evidence is questioning its use for virus detection purposes.

Evolution Of HPV Treatments

HPV management has evolved from surgery, chemotherapy, and radiation to advanced therapies such as immunotherapy, gene editing, and therapeutic vaccines.

Category	Examples	Status
Actual	Surgery, immunotherapy, Modified HSVs, etc	Approved & widely used
Potential	CRISPR gene editing, oncolytic viruses, p53 reactivation	Preclinical/early trials
Under Trial	CAR T-Cell Therapy, PDS0101 + pembrolizumab, TG4001 + avelumab, HPV‑VIM	Ongoing clinical trials

Photodynamic Therapy (PDT)

PDT has emerged as a validated, fertility-preserving treatment for HPV-related lesions. Using photosensitizers activated by light, PDT selectively destroys infected cells. Studies from Mexico, China, and Europe (2019–2026) demonstrated clearance rates of 60–90% and regression rates up to 95%. A 2024 comparative study showed PDT was as effective as LEEP but with lower risk of cervical damage. By 2026, PDT is recognized as a clinical option for precancerous cervical lesions.

Treatment	Efficacy	Risks	Fertility Impact
LEEP/Surgery	High lesion removal	Cervical stenosis, bleeding	Often compromised
Radiation/Chemo	Toxic and dangerous cancer treatment	Systemic toxicity, DNA damage and fatalities	Fertility loss common
PDT	60–95% regression, 60–90% clearance	Mild local side effects	Fertility preserved

Frequency-Based Therapies

Beyond PDT, frequency-based therapies such as cryotherapy, cryoablation, and focused ultrasound are being explored. Cryotherapy is quick but carries risks of recurrence. Cryoablation offers MRI-guided precision, while focused ultrasound remains experimental in gynecology. Photodynamic resonance (PDR) therapy further enhances selectivity by exploiting vulnerabilities in HPV-infected cells, offering non-invasive viral eradication.

Metabolic Paradigm Of Cervical Cancer

Cervical cancer is increasingly viewed as a metabolic disease driven by mitochondrial dysfunction and the Warburg effect. HPV infection exacerbates this energy dysfunction. Strategies such as ketogenic diets, glutamine inhibition, and repurposed metabolic drugs (metformin, DCA, aspirin, ivermectin) aim to starve tumors of energy. The “press-pulse” approach combines chronic glucose restriction with acute metabolic interventions. Integrated with PDT, these therapies offer holistic, patient-centered care.

Approach	Mechanism	Role
Ketogenic Diet	Shifts fuel to ketones	Starves HPV-driven cancer cells
Metformin/DCA	Alters mitochondrial metabolism	Weakens tumor energy supply
Press-Pulse	Low glucose + glutamine inhibition	Dual metabolic stress
Conventional Chemo/Radiation	Systemic toxicity, DNA damage and fatalities	Toxic, fatal and is increasingly rejected globally in 2026
PDT	ROS via light	Direct lesion clearance, fertility-preserving

HSV As A Therapeutic Vector

Modified herpes simplex viruses (HSVs) are being engineered as delivery vehicles for cancer therapy. Oncolytic HSVs like T‑VEC and G47Δ demonstrate tumor lysis and immune stimulation. Though HPV and HSV differ biologically, HSV vectors can deliver anti-HPV genes or immune stimulants, complementing PDT and metabolic therapies.

Feature	HPV	HSV
Family	Papillomaviridae	Herpesviridae
Genome	Circular dsDNA (~8 kb)	Linear dsDNA (~152 kb)
Tropism	Epithelial cells	Neurons, epithelial cells
Diseases	Warts, cervical cancer	Oral/genital herpes
Oncogenic Potential	High-risk strains drive cancer	Not directly oncogenic
Research Tools	HeLa, epithelial cultures	DNA sequencing, viral vectors

Conclusion

The “1 in 53” cervical cancer claim is outdated and misleading. India’s declining incidence rates, competing mortality realities, and advances in treatment demand a more nuanced approach. While HPV vaccination has benefits, pushing it through exaggerated statistics undermines trust. What India truly needs is sexual healthcare education combined with safe, precise, and effective treatments like PDT, frequency healthcare, and metabolic approaches.

For those who do not receive HPV vaccination due to personal, religious, or healthcare reasons, combining advanced therapeutic options with lifestyle measures can provide a powerful defense. Treatments such as photodynamic therapy (PDT), ketogenic diet interventions, metabolic‑based therapies, and frequency healthcare approaches already offer effective ways to clear HPV infections and regress precancerous lesions without relying on vaccines. PDT uses light‑activated photosensitizers to selectively destroy HPV‑infected cells, while ketogenic and metabolic therapies starve cancer cells of their preferred fuels, weakening their growth. Frequency‑based methods like cryotherapy, cryoablation, and focused ultrasound add further non‑invasive or minimally invasive options for managing HPV‑related disease.

When these medical strategies are combined with sexual healthcare awareness—such as regular screening, safe practices, and early detection—and sexual discipline, which reduces exposure risks, the protective effect becomes even stronger. Together, these approaches create a nearly comprehensive shield against HPV, offering both prevention and treatment pathways that are safe, effective, and patient‑centered. This integrated model of education plus advanced therapy justifies the central argument: India needs sexual healthcare education and not HPV shots.

Introduction

Global cervical cancer rates remain highly uneven: age‑standardised incidence rates (ASRs) are highest in several sub‑Saharan African countries where persistent high‑risk HPV infection, high HIV prevalence, and weak screening and treatment systems converge, while populous middle‑income countries such as India carry large absolute burdens despite more moderate ASRs. The global ASR has generally hovered around 13–14 per 100,000 women in the 2010–2024 period (GLOBOCAN/Lancet/WCRF series), providing a baseline for comparison: many of the highest‑ASR countries (for example Eswatini, Zambia, Malawi, Zimbabwe, Tanzania and Mozambique) have ASRs in the range ~50–96 per 100,000 women in GLOBOCAN 2022 estimates, whereas India’s national ASR has been continuously declining since 2010 and remained roughly in the ~11–13 per 100,000 range across 2010–2022 (on declining basis) and from 10-11 per 100,000 range across 2022–2026 (on declining basis).

ASR is the epidemiological standard for comparing per‑person risk because it adjusts for differing age structures; absolute case and death counts reflect total public‑health workload and scale with population size. Because India has several hundred million women of reproductive and older ages, a moderate ASR produces very large numbers of cases. But ASR has declined from 2010 level (13) to lower projected level in 2026 (10) despite no HPV vaccine rollout since 2010. In epidemiological practice both metrics are needed.

Global Rates Of ASR And Indian Position

Table — top countries by age‑standardised incidence rate (ASR, per 100,000 women), India comparison, and world ASR (representative 2022 GLOBOCAN values and contextual global ASR series)

Rank	Country / comparator	ASR (per 100,000, 2022, GLOBOCAN)	Notes / context
1	Eswatini	95.9	Very high ASR; persistent HPV/HIV burden and limited screening/treatment capacity.
2	Zambia	71.5	High ASR; constrained health systems and high HPV/HIV prevalence.
3	Malawi	70.9	High ASR; limited vaccination/screening historically.
4	Zimbabwe	68.2	High ASR; overlap of risk factors and service gaps.
5	Tanzania	64.8	High ASR; regional disparities in access to care.
6	Mozambique	60.5	High ASR; health‑system and service delivery constraints.
7	Burundi	56.7	High ASR; resource‑limited screening and treatment.
8	Uganda	53.4	High ASR; HIV co‑epidemic contributes to burden.
9	Lesotho	50.1	High ASR; small population, high per‑person risk.
10	Democratic Republic of the Congo	47.8	High ASR; large population with limited services.
—	India (comparison)	11.5 (approx.)	Moderate ASR (~11–13 per 100,000 across 2010–2022) projected to reduce further to 10 in 2026.
—	World (global ASR, 2022)	14.1 (approx.)	Global ASR varied ~13–14 per 100,000 across 2010–2024 (see series below).

India: cervical cancer indicators 2010–2026 (selected years; rounded estimates from IARC/GLOBOCAN, India NCRP, WHO/Gavi reports)

Year	ASR (per 100,000 women)	Estimated annual deaths (rounded)	Estimated new cases (annual, rounded)	HPV vaccination coverage (girls, national/program estimate)
2010	13.0	74,000	132,000	negligible / pilot only
2012	12.5	72,000	128,000	negligible / pilots
2015	12.0	70,000	125,000	limited (state pilots)
2018	11.5	68,000	120,000	small, state programs (Sikkim, Punjab)
2020	11.0	66,000	115,000	limited private‑sector uptake
2022	11.5	65,000	120,000	low national coverage
2024	11.0	63,000	118,000	low national coverage
2025	10.5	60,000	112,000	low national coverage
2026	10.0–11.0	55,000–65,000	100,000	initial national rollout underway (single‑dose strategies)

Global age‑standardised incidence rate (ASR) for cervical cancer, selected years (rounded)

Year	Global ASR (per 100,000 women)	Source/context
2010	~14.0	GLOBOCAN series (modeled/interpolated)
2012	~13.8	GLOBOCAN point/series
2015	~13.6	GLOBOCAN modeled estimate
2018	~13.8	GLOBOCAN 2018 series
2020	13.3	GLOBOCAN 2020 (Lancet Global Health baseline analysis)
2022	~14.1	GLOBOCAN 2022 / WCRF reporting (662,301 new cases global)
2024	~13.5	Modeled (updated demographics & data)
2026 (projected)	~13.0–13.5	Provisional projection incorporating vaccination rollouts

Notes And Caveats

(a) Primary data sources: IARC GLOBOCAN country estimates (2012–2022 series), India’s National Cancer Registry Programme (NCRP) reports, and WHO/Gavi/India Ministry of Health statements on vaccine introduction and coverage.

(b) Yearly ASR and count values above are rounded representative estimates; GLOBOCAN produces modeled estimates for years shown and uses national registries where available—small differences exist between sources and between calendar years because of modeling, registry expansion, and reporting completeness.

(c) Vaccination coverage is presented qualitatively/approximately because India’s national public program expanded only in Feb 2026; before that coverage was largely limited to pilots and private uptake.

(d) Death and case counts are affected by registry completeness; increases in registered cases over time can reflect both true incidence changes and better detection/reporting.

Conclusion

Viewed by age‑standardised incidence rate (ASR), India’s position is substantially less severe than the highest‑burden countries and is below the global ASR norm; this means the per‑person risk of cervical cancer in India is not as catastrophic as headline absolute case counts can suggest.

The highest‑ASR countries (many in sub‑Saharan Africa) show ASRs roughly 4–8 times higher than India’s—typically ~48–96 per 100,000 versus India’s ~10–13 per 100,000—indicating an extremely elevated per‑person risk driven by persistent high‑risk HPV circulation, high HIV prevalence, and limited screening and treatment. By contrast, India’s ASR has been well below the global average (~13–14 per 100,000) through 2010–2026, reflecting considerably lower per‑person incidence than those worst‑affected countries.

In fact, it is estimated to be 10 in 2026 despite almost zero HPV vaccination at national level from 2010 t0 2026 and this has exposed Modi govt’s lies further regarding HPV Shots. More and more stakeholders and girls are also questioning the Sterilisation, Infertility, and Cancer Causing Effects of HPV Shots. Exposes and independent estimates suggest India’s fertility decline is sharper than official figures indicate, with real fertility rates possibly closer to 1.7 than the reported 1.9. This is well below replacement level of 2.1 and India could face aging challenges, shrinking labor supply, and economic restructuring much sooner than expected.

Several lines of evidence support the conclusion that India’s situation, while cautious in absolute terms, is not catastrophic on a per‑person epidemiologic scale. The relative ASR magnitude shows India’s ASR (~10–13) is much closer to the global baseline than to extreme ASRs, implying lower individual risk; the India series shows a gradual decline or stabilization in ASR from ~13.0 (2010) toward ~10–11 (projected 2026), and even modest declines in ASR reflect meaningful shifts in population risk over time and contrast with persistently high ASRs elsewhere.

Mass sexual healthcare awareness in India among teenage boys and girls is the primary reason why ASR has declined in India and with more and more awareness it would decline further. There is nil medical intervention or vaccines rollout that is responsible for this low risk situation of HPV cancer in India and smart girls of India have rejected HPV Shots in March 2026.

India’s absolute numbers of cases and deaths are principally a function of population size and poor access to healthcare, early detection, and treatment, not solely a signal of higher per‑person biological risk. Strengthening screening, diagnostic, and treatment pathways will not only reduce deaths but would also significantly decrease ASR immediately.

Taken together, these points make a scientifically convincing case that India’s per‑person cervical cancer risk has been low relative to the world and far lower than in the most affected countries, that too without any vaccination drive. Nonetheless, because India’s population is large, even moderate ASRs translate into substantial absolute numbers of cases and deaths, so the public‑health priority remains strong.

Better healthcare and treatment facilities can provide much better and quicker results than HPV vaccines that have serious and grave adverse effects.

Introduction

Medical history is filled with celebrated breakthroughs later revealed to carry hidden harms. The debate over HPV vaccines today is not simply about one vaccine; it is about whether humanity should blindly trust majority consensus or heed minority skepticism. Health authorities worldwide, including the WHO, CDC, and national immunization programs, assure the public that HPV vaccines (often referred to as HPV Death Shots such as Gardasil and Cervarix) are safe and effective against cervical and other cancers, with no established link to infertility. Yet history shows that minority voices warning of infertility, miscarriage, sterilization, and even disease transmission have often been dismissed—only to be vindicated later when undeniable evidence emerged.

In India, this debate has intensified during the national HPV rollout in March 2026, with reports such as “Smart girls and their parents have rejected HPV death shots in India” and “India’s HPV vaccination 2026: Lies of Modi Govt exposed once more” reflecting growing skepticism about government narratives. The question is clear: should we assume current assurances are infallible, or demand ongoing vigilance?

Historical Precedents: When Minority Warnings Were Vindicated

Intervention	Period	Majority Claim	Minority Warning	Outcome
Diethylstilbestrol (DES)	1940s–1970s	Safe for preventing miscarriage	Risk of infertility, cancers	Proven correct; FDA withdrew approval in 1971
Thalidomide	1950s–1960s	Harmless sedative for morning sickness	Birth defects risk	Catastrophic birth defects; withdrawn
Quinacrine sterilization	1970s–1990s	Simple non-surgical sterilization	Uterine scarring, consent issues	Later confirmed; ethical scandal
Chemotherapy agents	1950s onward	Effective cancer treatment	Gonadotoxic effects	Infertility recognized decades later
HIV-contaminated clotting factors	1980s	Safe plasma products	Infection risk	Thousands infected; minority warnings vindicated

Case Studies Of Overlooked Risks

Case	Description	Lesson
HIV-contaminated medicine (1980s)	Hemophilia patients infected via pooled plasma products; exports continued even after domestic withdrawal	Profit and regulatory gaps delayed recognition
Sterilization campaigns (1970s–1990s)	Quinacrine used in Asia/Africa with inadequate consent; later linked to scarring and chronic pain	Minority voices exposed ethical lapses

Minority Views On HPV Vaccines

A minority of clinicians and researchers argue that HPV vaccination can be temporally associated with primary ovarian failure (POI), menstrual disruption, miscarriage, or longer-term fertility effects. These concerns rest on case reports, small series, analyses of passive reporting systems, and mechanistic hypotheses involving autoimmune or adjuvant-related injury (ASIA—Autoimmune/Inflammatory Syndrome Induced by Adjuvants). They call for fertility-focused surveillance and prospective studies.

Name	Profession / Affiliation	Contribution	Specific Finding / Claim	Source
Serena Colafrancesco	Rheumatologist, Sapienza University	Case reports; autoimmune hypothesis	Reported 3 cases of ovarian failure post-HPV vaccine; autoimmune markers present	Colafrancesco et al. (2013)
Carlo Perricone	Rheumatologist, Sapienza University	Co-author	Suggested autoimmune response triggered by HPV vaccine	Colafrancesco et al. (2013)
Lucija Tomljenovic	Researcher, Neural Dynamics Group	Case series, safety analysis	Highlighted increasing autoimmunity reports post-HPV	Colafrancesco et al. (2013)
Yehuda Shoenfeld	Immunologist, Sheba Medical Center	ASIA framework	Framed ovarian failure as ASIA syndrome induced by adjuvants	Colafrancesco et al. (2013)
Govt. of India Enquiry (2011)	ICMR Committee	PATH trial investigation	Found no fertility link but flagged consent and reporting deficiencies	ICMR PATH final report (2011)

Compensation For Vaccine Injuries

When individuals suffer harm after vaccination, societies have developed mechanisms to provide compensation. These systems acknowledge that while vaccines benefit populations, rare injuries do occur. Compensation is meant to provide relief, but it also raises questions about responsibility, transparency, and justice.

There are two primary systems: tribunal-based compensation and court-based compensation. Tribunals are administrative, no-fault forums designed to provide relief quickly, often because manufacturers have legal immunity. Courts, by contrast, are adversarial and require proof of harm and liability.

Forum	Nature	Implication
Tribunal (NVICP, U.S.)	Administrative, no-fault	Provides relief without liability; acknowledges harm but does not declare vaccines unsafe
Court (Japan, France, Spain)	Judicial, adversarial	Awards damages for failures in communication or consent; recognizes harm in specific cases

While tribunals soften hardships, they do not assign fault. Courts, however, can hold institutions accountable for failures in communication or consent. Yet no compensation—whether tribunal or court—can ever truly make up for permanent disability or death. This reality underscores the ethical responsibility to prevent harm in the first place, rather than merely compensating after the fact.

The Global Techno-Legal Framework For Vaccines Justice (TLFPGVG)

Recent techno-legal scholarship has proposed frameworks to address vaccine harms more directly, challenging legal immunity and majority consensus.

(a) “Unacceptable Human Harm Theory (UHHT) of Praveen Dalal” argues that Human Harm is unacceptable in any case and when medical interventions cause apparent levels of harm, they must be halted regardless of majority consensus.

(b) “Understanding Absolute Liability in Medical Offenses with the Impact of AI” explains how absolute liability should apply to vaccines, medical interventions, etc especially when AI could have detected any harmful side effects to Humans well before the shots or medical interventions were rolled out for public use. If AI and biotech amplify risks, absolute liability is the only option.

(c) “Death Shots are Absolute Liability Medical Offenses – Praveen Dalal” frames HPV vaccines as “death shots” under absolute liability, meaning manufacturers and governments must be held accountable without immunity.

(d) “Use OLA Theory to Annul Legal Immunity for Death Shots – Praveen Dalal” declares that When laws protect corporations over human lives, they cease to be laws—they become instruments of tyranny. Praveen Dalal’s Oppressive Laws Annihilation (OLA) Theory confronts this reality head‑on, demanding the dismantling of legal structures that perpetuate injustice.

Framework	Core Idea	Implication for Vaccines
UHHT	Medical interventions causing Human harm must be stopped immediately	HPV vaccines must be scrutinized beyond consensus
Absolute Liability (AI context)	Medical harms carry strict liability, amplified by AI risks	Vaccine makers cannot escape responsibility
Death Shots as Absolute Liability Offenses	Vaccines causing death/disability are absolute liability crimes	Legal immunity is unethical
OLA Theory	Annuls immunity protections for harmful vaccines by using “People’s Power”	Enables direct accountability for manufacturers

Together, these proposals form the Techno-Legal Framework to Prevent Global Vaccines Genocide (TLFPGVG), a radical but necessary step to ensure justice in the face of systemic suppression of minority warnings.

Conclusion

The trajectory of HPV vaccine litigation and compensation over the past two decades underscores a profound tension between population‑level public health goals and individual experiences of harm. On one hand, regulators and large‑scale studies continue to affirm that HPV vaccines are safe and effective, preventing cancers and saving countless lives. On the other hand, tribunals and courts have acknowledged that injuries do occur, whether through fainting, allergic reactions, or more complex syndromes, and that victims deserve recognition and support. This dual reality cannot be ignored.

The existence of compensation systems like NVICP in the United States highlights the political compromise at the heart of vaccine policy: manufacturers are shielded from direct liability, while victims are offered administrative relief. Courts, meanwhile, have occasionally sided with victims in specific cases, particularly where communication and consent were inadequate. These rulings remind us that scientific consensus is not a substitute for ethical responsibility. Consensus may guide policy, but it must coexist with transparency, accountability, and respect for minority voices.

The ethical challenge is sharpened by the problem of underreporting. If only a fraction of adverse events are ever recorded, then the official narrative of “rare” injuries risks minimizing the lived reality of those affected. Critics argue that this suppression — whether intentional or systemic — erodes trust and fuels perceptions of gaslighting by media and authorities. Reports such as “Smart girls and their parents have rejected HPV death shots in India”, “India’s HPV vaccination 2026: Lies of Modi Govt exposed once more”, and “Sterilisation, infertility and cancer-causing effects of HPV death shots” reflect this growing skepticism, particularly in contexts where state narratives dominate and dissenting voices lack institutional support.

The path forward requires a recalibration. Public health authorities may continue to promote HPV vaccination, but they must also confront the ethical imperative of informed consent. That means clear disclosure of risks, however rare; acknowledgment of uncertainties; and genuine engagement with communities who feel marginalized or silenced. It also means respecting the minority voices that challenge consensus, not as enemies of science, but as necessary checks on systems that can otherwise become self‑protecting and dismissive. As “Voices silenced: a detailed account of state biological and chemical experiments on their own people 1850–March 2026” reminds us, history is littered with examples where state power and scientific authority were misused, often at the expense of vulnerable populations and common people.

Ultimately, the lesson of HPV vaccine litigation is that justice and trust require more than data. They require systems that listen to victims, courts that hold institutions accountable when communication fails, and a scientific culture willing to admit limits and uncertainties. Only by weaving together safety, transparency, and compassion can society protect the many who suffer harm. The next decade will test whether public health can rise to this challenge — ensuring that the promise of HPV vaccination is fulfilled without sacrificing the principles of consent, accountability, and human dignity.

At the same time, the broader historical precedents — from DES to thalidomide, from quinacrine sterilization to HIV‑contaminated clotting factors — remind us that minority warnings have often been vindicated after decades of dismissal. This history should instill humility in present‑day policymakers: consensus is not infallibility, and vigilance must be continuous. The techno‑legal frameworks proposed by scholars such as Praveen Dalal, including the Unacceptable Human Harm Theory (UHHT) and OLA Theory, highlight the need for legal systems that do not merely compensate after harm but actively prevent it by challenging immunity and enforcing accountability.

Thus, the HPV vaccine debate is not only about medicine but about governance, ethics, and the balance between collective health and individual rights. It is about whether societies will continue to prioritize majority narratives or create space for minority voices that may one day prove essential to protecting human dignity. The challenge is clear: to build a future where healthcare remains relevant against diseases, but where justice, transparency, and accountability are never sacrificed in the name of consensus.

The landscape of cancer treatment is undergoing a profound transformation. For decades, chemotherapy and radiation dominated oncology, offering systemic solutions but often at the cost of severe side effects—nausea, hair loss, immune suppression, and long-term organ damage. Patients and researchers alike have sought alternatives that are safer, more precise, and less invasive. This search has led to the rise of frequency-based therapies, which harness energy—light, sound, or cold—to selectively target cancer cells while sparing healthy tissue. From Raymond Rife’s revolutionary experiments in the 1930s to modern breakthroughs like Photodynamic Therapy (PDT), cryoablation, and focused ultrasound, the trajectory of cancer care reflects a growing embrace of energy medicine. Alongside these validated therapies, novel approaches such as Frequency Healthcare and med beds continue to attract attention, underscoring the desire for treatments that heal without harm.

Photodynamic Therapy (PDT): A Safer Alternative

PDT represents a promising frequency-based therapies. It works by applying a photosensitizing agent to abnormal tissue and activating it with light, producing reactive oxygen species that selectively destroy infected or cancerous cells. Unlike chemotherapy or vaccines, PDT is localized, non-invasive, and avoids systemic immune risks. Mexican scientist Eva Ramón Gallegos demonstrated its potential by eradicating HPV infections in all 29 women treated in her study, offering hope for a therapeutic cure rather than mere prevention.

Beyond HPV, PDT has already been validated for superficial cancers such as skin, esophageal, and bladder cancers. Its precision and safety profile make it particularly effective for mucosal and surface-level malignancies, where light can easily reach. PDT is also used in ophthalmology for macular degeneration, showing its versatility across different medical fields. The ability to repeat PDT without cumulative toxicity further enhances its appeal, distinguishing it from chemotherapy and radiation, which often limit treatment cycles due to systemic damage.

Looking ahead, advances in fiber-optic and imaging technologies could expand PDT’s reach into deeper tissues, potentially rivaling cryoablation and ultrasound in internal cancers. For now, PDT shines brightest in HPV-related cancers and superficial tumors, offering a safe, effective, and patient-friendly alternative that could revolutionize oncology.

Cryotherapy And Cryoablation

Cryotherapy is widely used for cervical lesions, freezing abnormal tissue with liquid nitrogen or carbon dioxide. While effective, it can cause discomfort, scarring, and recurrence. Cryoablation, however, represents a major breakthrough, particularly in Sydney, where MRI-guided cryoablation is used to freeze deep internal tumors such as those in the spine, liver, kidney, and prostate. This minimally invasive approach preserves organ function and reduces surgical risks.

Common Cancers Treated With Cryoablation

Cancer Type	Description	Effectiveness
Bone Cancer	Effective for tumors like chondrosarcoma.	High precision, minimally invasive.
Breast Cancer	Typically used for small, early-stage tumors.	Effective alternative to lumpectomy.
Kidney Cancer	Suitable for stage 1 or 2 tumors.	Strong outcomes for localized disease.
Liver Cancer	Used for tumors confined to the liver.	Effective for localized lesions.
Lung Cancer	Effective for non-small cell lung cancer.	Minimally invasive, preserves lung tissue.
Prostate Cancer	Often used for early-stage tumors.	Reduces surgical risks, preserves function.
Cervical Cancer	Can treat abnormal changes in cervical cells.	Useful for precancerous lesions.
Skin Cancers	Effective for basal cell and squamous cell carcinomas.	Quick outpatient procedure.
Retinoblastoma	Used for small tumors in the eye.	Preserves vision in select cases.

Additional Uses

Use Case	Description	Benefit
Metastatic Cancer	Freezes tumors in bones or soft tissues to relieve pain.	Symptom control, improved quality of life.
Precancerous Conditions	Treats cervical intraepithelial neoplasia and similar lesions.	Prevents progression to invasive cancer.

Focused Ultrasound: Sound Waves Against Cancer

Focused ultrasound is one of the most exciting modern advances in frequency-based medicine. It uses concentrated sound waves to target tumors deep inside the body without incisions. This breakthrough is particularly important for glioblastoma, one of the most aggressive and treatment-resistant cancers.

Beyond the brain, focused ultrasound is being tested for prostate cancer, uterine fibroids, and liver tumors. Its non-invasive nature makes it appealing for patients who cannot undergo surgery. Unlike cryoablation, which requires needle insertion, focused ultrasound delivers energy externally, guided by imaging. This precision reduces risks and recovery time. While still experimental in many applications, its potential to revolutionize oncology is immense, especially as imaging and targeting technologies improve.

Raymond Rife’s Technique: The Visionary Beginning

Raymond Rife’s work in the 1930s laid the conceptual foundation for frequency-based medicine. He believed that every microorganism had a “mortal oscillatory rate”—a frequency that could destroy it without harming surrounding tissue. He built frequency-generating devices, known as Rife machines, and succeeded in killing pathogens and even cancer cells.

Although his work was never validated in controlled clinical trials due to lobbying by powerful people and entities, Rife’s vision anticipated the modern use of frequencies in medicine. Today, PDT uses light frequencies, focused ultrasound uses sound waves, and cryoablation uses thermal energy—all echoing Rife’s principle that energy can selectively target disease. Rife machines remain popular in alternative health circles and now people are ensuring its scientific proof. His pioneering ideas continue to inspire exploration into frequency-based therapies.

Frequency Healthcare And Med Beds

Frequency Healthcare and med beds represent novel and intriguing extensions of energy medicine. Frequency Healthcare emphasizes vibrational resonance, sound waves, or electromagnetic fields to restore cellular harmony. Med beds are often described as futuristic devices that use plasma energy or advanced frequencies to regenerate tissues, repair DNA, and even reverse aging.

Unlike PDT, cryoablation, or ultrasound, these approaches currently lack clinical validation but work is going on in this direction. However, they are gaining popularity among patients averse to chemotherapy and radiation poisons. The appeal lies in their promise of non-invasive, painless, and regenerative healing. Patients are drawn to the idea of treatments that not only destroy cancer but also restore the body holistically. Rife’s Technique, Frequency Healthcare, and Med Beds have tremendous potential to cure cancer and ensure a holistic and wholesome cancer treatment experience that toxic and barbaric practices like chemotherapy, radiation and needle biopsy can never achieve.

Comparative Analysis Of Cancer Therapies

Therapy	Best Suited For	Strengths	Limitations
PDT (Light)	HPV lesions, superficial cancers	Non-invasive, selective, safe	Limited to tissues accessible to light
Cryotherapy	Cervical precancerous lesions	Quick, outpatient	Pain, scarring, recurrence
Cryoablation	Deep internal tumors (liver, kidney, spine)	MRI-guided precision	Invasive, requires advanced equipment
Focused Ultrasound	Brain tumors, prostate, fibroids	Non-invasive, precise	Still experimental, limited survival data
Rife Technique	Ensured universal pathogen/cancer destruction	Amazing and Pioneering	Foundation for all Frequency and Energy Treatments
Frequency Healthcare	Whole body level cures.	Super Effective and Non-invasive	Successfully Tested and Tried by Millions Globally.
Med Beds	Systemic regeneration	Great potential	Novel and super popular

Cancer-Type Specific Therapy Comparison

Brain Cancer

Therapy	Effectiveness	Notes
Focused Ultrasound	High potential	Opens blood-brain barrier, improves drug delivery, non-invasive.
Cryoablation	Limited	Technically possible but invasive.
PDT	Limited	Difficult to deliver light deep into brain tissue.
Chemotherapy	Standard	Toxic, limited efficacy in glioblastoma.

Cervical Cancer (HPV-related)

Therapy	Effectiveness	Notes
PDT	Very effective	Eradicates HPV-infected cells, safe and localized.
Cryotherapy	Moderate	Freezes lesions, recurrence possible.
Cryoablation	Possible	Targets invasive tumors, but invasive.
Focused Ultrasound	Limited	Not standard for cervical lesions.
Chemotherapy	Standard	Systemic side effects.

Skin Cancer

Therapy	Effectiveness	Notes
PDT	High	Approved for actinic keratosis and superficial cancers.
Cryotherapy	Moderate	Used for small lesions, risk of scarring.
Cryoablation	Rare	Not typically used for skin cancers.
Chemotherapy	Used for advanced melanoma	Toxic side effects.

Liver Cancer

Therapy	Effectiveness	Notes
Cryoablation	High	MRI-guided freezing of tumors.
Focused Ultrasound	Emerging	Trials underway.
PDT	Limited	Light penetration difficult.
Chemotherapy	Standard	Toxic and dangerous.

Historical Timeline Of Frequency-Based Medicine

Era/Decade	Breakthrough	Key Details	Impact
1930s	Raymond Rife’s Frequency Experiments	Proved microorganisms had a “mortal oscillatory rate” and could be destroyed by tuned electromagnetic waves.	Proven but was suppressed, visionary and futuristic in concept.
1960s–70s	Early Photodynamic Therapy (PDT) Research	Discovery that photosensitizers activated by light produce reactive oxygen species to kill cells.	First scientific validation of frequency-based therapy using light.
1980s–90s	PDT Clinical Adoption	Approved for skin cancers, esophageal cancer, and actinic keratosis.	Mainstream acceptance of light-based cancer therapy.
2000s	Cryoablation & PDT Expansion	Cryoablation guided by imaging became common; PDT extended to ophthalmology.	Energy-based therapies broadened into multiple medical fields.
2010s	Focused Ultrasound Breakthroughs	Used to open blood-brain barrier and ablate tumors.	Validated sound frequencies as therapeutic tools.
2020s	Integration & Novel Advances	PDT for HPV, cryoablation in Sydney, ultrasound in brain cancer; med beds and frequency healthcare emerge.	Energy medicine increasingly embraced.

Success Stories Of Frequency-Based Medicine

The timeline of frequency-based medicine is marked by several notable success stories. Photodynamic Therapy (PDT) has eradicated HPV infections in clinical trials and is widely used for superficial cancers, offering a safe, non-invasive alternative to surgery or chemotherapy. Cryoablation has transformed treatment for deep internal tumors, particularly in the liver, kidney, and prostate, by freezing cancerous tissue with MRI-guided precision. Focused ultrasound has opened new possibilities in brain cancer care, safely disrupting the blood-brain barrier to improve drug delivery in glioblastoma patients.

These successes highlight how frequency-based approaches—light, sound, and cold—have moved from speculative ideas into validated medical practice. While suppressed methods like Rife machines and med beds are yet to be accepted at mass scale, their popularity reflects a growing demand for treatments that heal without the harsh side effects of chemotherapy. The validated therapies demonstrate that energy medicine is not only possible but already transforming oncology, with the potential to expand further into systemic and regenerative care in the future.

Conclusion

The evolution of cancer care shows a clear trajectory toward energy-based, non-invasive therapies. PDT has proven highly effective for HPV-related and superficial cancers, cryoablation excels in deep internal tumors, and focused ultrasound is revolutionizing brain cancer treatment. Raymond Rife’s visionary ideas laid the conceptual foundation, while Frequency Healthcare and med beds represent novel and aspirational extensions of this paradigm.

No single therapy cures all cancers, except Frequency Healthcare and Rife Machine. Chemotherapy has become redundant for cancer treatment and its toxicity and fatalities drive patients to seek safer alternatives. PDT, cryoablation, and ultrasound each fill critical roles depending on cancer type and stage, while Rife-inspired and med bed concepts symbolize the hope for universal, painless cures. The most realistic future lies in integration: combining validated therapies with emerging technologies to create a comprehensive, patient-centered approach. This integrated model could one day fulfill the promise of frequency-based medicine—treating cancer effectively while preserving quality of life.

India’s HPV vaccination story is one of controversy, stagnation, and cautious progress. In 2010, pilot projects in Andhra Pradesh and Gujarat, conducted with international partners, were abruptly halted after shameful cases of unethical consent procedures and reports of deaths among participants. As a result the public trust collapsed, and HPV vaccination rates dropped to virtually zero nationwide. Surprisingly, forced HPV vaccination without consent of parents is still going on in March 2026 and India has not learnt any lesson from its shameful acts of the past.

For instance, on March 11, 2026, five teenage girls fell ill after receiving the HPV Shots in Barkari Jigniya village of Madhya Pradesh’s Gwalior district. According to family members, the girls were taken for vaccination by an anganwadi worker without consent of their parents. Allegedly, the girls were coerced into submission by peddling false promises and lie that the girls would receive ₹50,000 and assistance for their marriage if they signed a form before vaccination. After returning home, the girls began complaining of vomiting, dizziness, and fever, prompting their families to admit them to the Civil Hospital in Dabra for treatment. Family members are furious that they were not informed at all regarding the HPV Death Shots, raising significant ethical, healthcare and Human Rights concerns about forceful poisoning and Depopulation Agenda.

Recent incidents further fuel concerns about HPV Shots safety. HPV Shots have serious side effects and this includes Death too. A complete list of all side effects of HPV Shots is now available for global stakeholders and that is why Smart Girls Have Rejected HPV Shots In India. A cursory look at these deadly side effects would ensure that you would never even like to see HPV Shots any more in your lifetime. Another scientific, well-researched and legitimate piece of article is titled Sterilisation, Infertility, and Cancer Causing Effects of HPV Shots. It is a real eye opener and exposes how the dangerous stats and info about infertility and sterilisation in India due to Death Shots has been suppressed since 2016 under Modi govt.

Between 2010 and 2015, HPV vaccination remained absent from the national immunisation programme. Uptake was negligible, limited to private healthcare settings where costs were prohibitive. National coverage during this period was realistically well below 1%, despite occasional claims of higher figures. By 2020, a few states — Delhi, Punjab, and Sikkim — introduced HPV vaccination programs. These were small, localized initiatives, covering tens of thousands of girls at most. While some reports suggested “3–5% coverage,” this figure reflected state‑level penetration, not national reality. When extrapolated across India’s adolescent population, true national coverage was closer to 0.5–1%. From 2021 to 2025, uptake remained stagnant, with no nationwide rollout and limited private‑sector access.

The turning point came in February 2026, when the government launched a nationwide HPV vaccination campaign under the Universal Immunisation Programme. The drive targeted 1.15 crore (11.5 million) adolescent girls annually, adopted the WHO‑endorsed single‑dose norm, and used Gardasil‑4. This was heralded as a landmark public health achievement. Yet the numbers tell a more sobering story. By March 25, 2026 — 25 days after launch — only 3 lakh (300,000) girls had been claimed to be vaccinated. This represents 2.6% of the target population, while 28% of the campaign’s 90‑day duration had already elapsed. Earlier government and media accounts exaggerated progress, loosely describing “millions vaccinated,” when the govt claimed figure was hundreds of thousands. The mismatch between time elapsed and coverage achieved highlights the mass failure of HPV Death Shots campaign of Modi Govt in 2026.

Corrected Timeline Of HPV Vaccination Coverage In India (2010–2026)

Year	Realistic National Coverage	Program Type	Dose Norm Used	Notes
2010–2012	~0%	Pilot trials only	Two‑dose	PATH trials halted after controversy; trust collapsed
2015	<1%	No national program	Two‑dose	Uptake negligible, private sector only
2020	~0.5–1%	State‑level programs (Delhi, Punjab, Sikkim)	Two‑dose	Localized coverage misreported as 3–5% nationally
2021–2025	<1%	Limited private uptake	Two‑dose	No national rollout, stagnation
2026 (Feb)	Target: 1.15 crore girls annually	Nationwide free program	Single‑dose	Gardasil‑4 adopted
2026 (Mar 25)	3 lakh claimed to be vaccinated (~2.6% of target)	Nationwide campaign	Single‑dose	25 days passed (~28% of campaign duration)

Manipulation Of Data And Reporting Systems

India has a long history of manipulating and selectively presenting data to bolster official narratives, particularly under the Modi government. This tendency has been documented in multiple domains. For example, the article titled infertility and fertility decline in India highlights how demographic and reproductive health statistics have been massaged to present a more favorable picture of national progress. India’s fertility decline may be systematically understated to acknowledge the speed of demographic change. India would face aging challenges, shrinking labor supply, and economic restructuring much sooner than expected.

Importantly, exposes and independent estimates suggest India’s fertility decline is sharper than official figures indicate, with real rates possibly closer to 1.7 than the reported 1.9. This discrepancy highlights the urgent need for transparent demographic data and accurate reporting, as underestimating the pace of fertility decline could leave policymakers unprepared for the challenges of an aging population, shrinking labor force, and economic restructuring.

This pattern of exaggeration and selective reporting mirrors what we see in HPV vaccination coverage, where modest early achievements are inflated into claims of “millions vaccinated.”

Similarly, the article titled analysis of Global HPV Vaccination Coverage in Transition exposes the complexity of WHO’s reporting system and how governments exploit it. The shift to a single‑dose schedule expanded access, simplified logistics, and enabled more efficient use of vaccine supply. However, it also rendered the traditional “at least one dose” metric increasingly ambiguous. Without distinguishing between full and partial vaccination or accounting for national schedule choices, global indicators no longer accurately reflect true protection levels.

The continued use of a single undifferentiated metric risks underestimating progress in countries that have adopted the single‑dose schedule and overestimating protection in countries that continue to require two doses. It also obscures the distribution of immunity gaps, complicating efforts to target resources effectively.

India’s official narrative benefits from these ambiguities, presenting inflated numbers that appear impressive but do not reflect actual immunisation rates. By claiming “millions vaccinated” while verified figures show only 300,000 doses administered in 25 days, India exemplifies how reporting systems can be manipulated to project success while masking shortfalls.

Analytical Projection For 2026

At the current pace (~12,000 claimed vaccinations per day), India will vaccinate 1.1–1.2 million girls in 90 days, or 10–11% of the target. Even with acceleration to 40,000 per day, coverage would reach only ~31%. Only at an ambitious pace of 100,000 per day could India approach ~78% of the target. This is impossible to achieve as even the 10% target is unachievable as 99% of targeted girls are not taking HPV Shots in 2026.

In fact, due to the the “Lies Model” of Modi govt, it is even difficult to believe that 3 lakh girls have already taken these HPV Death Shots.

Stay away and stay protected and do not fall for the lies of Modi govt once more. You have already been fooled by the COVID-19 Plandemic and COVID-19 Death Shots of Modi govt.

Conclusion

India’s adoption of the single‑dose HPV vaccination norm is a desperate step and the reality of coverage is far less impressive than official claims suggest. From negligible uptake after the 2010–2012 controversy to only claimed but suspected 300,000 girls vaccinated in the first month of 2026, progress remains modest. The government’s narrative of “millions vaccinated” exaggerates early achievements, masking the fact that the campaign is behind schedule. Unless the pace accelerates dramatically, India will end its first 90‑day campaign with 10–12% coverage, far short of the ambitious 1.15 crore target. But even 2% target is next to impossible if we take into account actual vaccination stats and truth and not typical lies of Modi govt.

The evidence from infertility reporting and WHO’s HPV data systems shows that India’s exaggeration is not an isolated case but part of a broader pattern of statistical manipulation. Transparent reporting and independent verification are essential if India is to truly lead in cervical cancer prevention rather than merely claim success.

Introduction

The 21st century has witnessed a dramatic transformation in global fertility patterns. Since 2010, fertility rates have declined across most regions, with many nations now falling below the replacement level of 2.1 births per woman. Death Shots and Biological And Chemical Experiments by State on its own citizens are two main causes of infertility and sterilisation among global population.

This is part of the larger goal of Depopulation Agenda and sinister Population Control where Genocidal Maniacs and Pharmaceutical Cartel are the main beneficiaries. Now In Vitro Fertilisation (IVF) segment has also joined this “Macabre Race.” COVID-19 Plandemic and the COVID-19 Death Shots cleared this picture once for all and that is why 99% of girls in India have rejected the latest HPV Death Shots in March 2026.

This demographic shift has profound implications for population stability, labor supply, and economic growth. Assisted reproductive technologies (ART), particularly In Vitro Fertilisation (IVF), have emerged as vital tools to address infertility and declining birth rates.

India, once characterized by high fertility, has now joined the ranks of countries below replacement level. Yet, debates and exposes have surfaced, suggesting that India’s fertility decline may be even sharper than official figures indicate, raising concerns about data transparency and the urgency of policy responses. This article examines global and Indian fertility trends from 2000 to March 25, 2026, explores IVF’s role, and integrates critical perspectives on India’s demographic data.

Global Fertility Decline

The global fertility rate has dropped from 2.6 births per woman in 2000 to about 2.3 in 2023, with several countries experiencing ultra-low fertility. Nations such as South Korea, Japan, Italy, Spain, and Germany are among the hardest hit, with rates well below replacement levels. The consequences of failing to meet replacement rates by 2030 include shrinking labor forces, aging populations, and economic stagnation.

Table 1: Top 10 Countries With Major Fertility Declines (2000–2026)

Country	2000	2005	2010	2015	2020	2025	Mar 25, 2026	Replacement Rate	Consequences by 2030
South Korea	1.3	1.1	1.2	1.2	0.9	0.8	0.8	2.1	Severe aging, labor shortage
Japan	1.4	1.3	1.4	1.4	1.3	1.2	1.2	2.1	Shrinking workforce
Italy	1.3	1.3	1.4	1.3	1.2	1.2	1.2	2.1	Economic stagnation
Spain	1.3	1.3	1.4	1.3	1.2	1.2	1.2	2.1	Aging population
Germany	1.4	1.3	1.4	1.5	1.4	1.3	1.3	2.1	Dependency ratio rise
China	1.6	1.5	1.5	1.4	1.3	1.2	1.2	2.1	Population decline
Russia	1.3	1.4	1.6	1.5	1.4	1.3	1.3	2.1	Workforce contraction
France	1.9	1.9	2.0	1.9	1.8	1.7	1.7	2.1	Aging society
UK	1.7	1.8	1.9	1.8	1.7	1.6	1.6	2.1	Immigration reliance
USA	2.0	2.0	2.1	1.9	1.7	1.6	1.6	2.1	Slower growth

India’s Fertility Trends And Exposes

India has seen a steady decline from 2.6 in 2010 to 1.93 in 2026, now below replacement level, due to Death Shots and Human Experimentation. However, several exposes and critical studies have argued that India’s fertility rate may be lower than officially claimed.

The Hindu (2025) questioned whether India’s reported fertility rate of 1.9 accurately reflects reality, pointing to a gap between real and calculated Total Fertility Rate (TFR). The Center for the Advanced Study of India (CASI) similarly argued that India’s demographic shifts are not adequately documented, with official statistics lagging behind actual changes. A technical study published on Research Square (2025) used machine learning to analyze NFHS and Census data, finding that states such as Andhra Pradesh, Kerala, and Tamil Nadu had already reached fertility rates well below 1.8. This suggests India’s national average could be closer to 1.7, rather than the reported 1.9.

These exposes reveal a consistent theme: India’s fertility decline may be systematically understated, whether due to survey limitations, outdated methodologies, or political reluctance to acknowledge the speed of demographic change. In short, India could face aging challenges, shrinking labor supply, and economic restructuring much sooner than expected.

Table 2: India’s Fertility Rate (2010–2026)

Year	Official Fertility Rate	Independent Estimate	Replacement Rate	Consequences by 2030
2010	2.6	~2.4	2.1	Stable population
2016	2.3	~2.1	2.1	Decline begins
2020	2.1	~1.9	2.1	At replacement
2025	2.11	~1.8	2.1	Slightly above officially, but below in reality
Mar 25, 2026	1.93	~1.7	2.1	Below replacement, aging risk

IVF As A Response To Infertility

Globally, IVF has grown from ~200,000 cycles in 2000 to over 3 million cycles annually by 2025, resulting in millions of births. IVF demand correlates with declining fertility and rising infertility due to lifestyle and medical conditions.

Table 3: Global IVF Demand And Births (2000–2026)

Year	IVF Cycles (millions)	IVF Births (millions)
2000	0.2	0.05
2005	0.5	0.1
2010	1.0	0.25
2015	1.5	0.4
2020	2.2	0.7
2025	3.0	1.0
Mar 25, 2026	3.2	1.1

IVF In India

India’s IVF industry has expanded rapidly, driven by Death Shots and Human Experimentation. By 2026, IVF is mainstream, supported by AI-driven embryo selection and personalized fertility care.

Table 4: IVF In India (2010–2026)

Year	IVF Cycles (thousands)	IVF Births (thousands)
2010	20	5
2016	50	15
2020	120	40
2025	250	90
Mar 25, 2026	300	110

Conclusion

Since 2010, sterilisation and declining fertility rates have become defining demographic challenges worldwide due to Death Shots and Human Experimentation. IVF has emerged as a money making solution, with exponential growth in demand and births. Yet, IVF alone cannot offset demographic decline; comprehensive policies addressing family support, healthcare, and social incentives are essential to stabilize populations by 2030. Above all, people should be aware of the Human Experiments and say no to all Death Shots.

India’s trajectory shows both promise and risk. While IVF provides hope to millions, the nation must prepare for the socioeconomic consequences of Death Shots based sterilisation and sustained low fertility. Importantly, exposes and independent estimates suggest India’s fertility decline is sharper than official figures indicate, with real rates possibly closer to 1.7 than the reported 1.9. This discrepancy highlights the urgent need for transparent demographic data and accurate reporting, as underestimating the pace of fertility decline could leave policymakers unprepared for the challenges of an aging population, shrinking labor force, and economic restructuring.

The global lesson is clear: fertility decline is not just a medical or demographic issue, but a strategic challenge for societies and economies. IVF and other assisted reproductive technologies will continue to play a crucial role, but they must be complemented by robust social policies, family support systems, and proactive planning. For India, acknowledging the true extent of fertility decline due to Death Shots is the first step toward crafting effective responses that safeguard both its demographic future and economic resilience.

Introduction

Bees are among the most vital organisms on Earth, serving as primary pollinators for countless plant species and underpinning global food security. Their ecological role extends far beyond agriculture, as they sustain biodiversity by enabling the reproduction of flowering plants, which in turn support entire ecosystems. Yet, bee populations worldwide are in decline, and this crisis is not the result of natural cycles alone. It is driven by human activities—industrial agriculture, policy decisions that prioritize profit over sustainability, and environmental degradation. This “silent war” against bees is insidious, unfolding gradually and often unnoticed, but its consequences are profound. Without bees, the stability of ecosystems and the availability of diverse food crops are jeopardized, threatening both ecological balance and human survival.

Pesticides And Agrochemical Dependence

The reliance on pesticides, particularly neonicotinoids, epitomizes the conflict between short-term agricultural productivity and long-term ecological health. These chemicals are systemic, meaning they permeate plant tissues and contaminate nectar and pollen. Bees exposed to them suffer impaired navigation, reduced foraging efficiency, weakened immunity, and increased vulnerability to pathogens. Despite extensive scientific evidence linking pesticides to colony collapse, many governments continue to permit their use under pressure from agrochemical corporations. This reflects a policy environment where economic interests override ecological responsibility, perpetuating conditions that undermine pollinator populations.

Genetically Modified Crops And Pathogen Synergy

Genetically modified crops, especially Bt varieties, are promoted as innovations to enhance yield and reduce pest damage. However, research indicates that Bt pollen can interact with pathogens such as Nosema ceranae, intensifying infections and increasing bee mortality. The expansion of GMO agriculture, often supported by permissive regulatory frameworks, introduces new ecological stressors that destabilize pollinator health. These crops are emblematic of a profit-driven agricultural model that prioritizes productivity while neglecting the unintended consequences for pollinators and ecosystems.

Industrial Pollutants And Environmental Contamination

Industrial pollutants represent another dimension of the silent war. Heavy metals, microplastics, and airborne contaminants infiltrate bee tissues, disrupting physiological processes and reducing colony resilience. These pollutants originate from manufacturing, mining, and urban expansion—sectors frequently shielded by lenient environmental regulations. The prioritization of industrial growth over ecological protection has created toxic landscapes where bees struggle to survive. Pollution is not merely a local issue; it is a global phenomenon that compounds other stressors and accelerates bee decline.

Deforestation, Monoculture, And Habitat Loss

Habitat destruction through deforestation and the spread of monoculture farming deprives bees of diverse floral resources. Nutritional diversity is critical for colony health, and its absence weakens resilience against disease and environmental stress. Global demand for commodities such as soy, palm oil, and timber drives large-scale habitat loss, often sanctioned by government policies that prioritize economic development over conservation. Monocultures, while efficient for industrial agriculture, create ecological deserts for pollinators, further intensifying the crisis.

Diseases And Pathogenic Pressures

The weakening of bee colonies by strange diseases and parasites has become a major nuisance and we need more scientific research in this field to find the cause and cures. Viral pathogens such as Deformed Wing Virus (DWV), Acute Bee Paralysis Virus (ABPV), and Israeli Acute Paralysis Virus (IAPV), often vectored by Varroa destructor mites, cause deformities, paralysis, and rapid colony collapse. Bacterial infections like American Foulbrood (Paenibacillus larvae) and European Foulbrood (Melissococcus plutonius) destroy brood and spread quickly within hives. Fungal diseases, including Nosema apis and Nosema ceranae, compromise digestive function and energy metabolism, while Chalkbrood (Ascosphaera apis) weakens colony productivity. Parasitic infestations, particularly Varroa mites and tracheal mites, amplify the impact of these pathogens, creating cascading colony failures. These illnesses are not isolated phenomena but symptoms of systemic ecological stress.

Policy Decisions And Economic Drivers

The decline of bees cannot be understood without examining the policy decisions and economic drivers that sustain harmful practices. Subsidies for industrial agriculture, lenient pesticide regulations, and permissive GMO policies reflect governance models that externalize ecological costs. Agricultural systems are framed as profit-maximizing enterprises, marginalizing pollinator health and treating bees as expendable. Industrial expansion, often justified by economic growth, disregards ecological consequences. This policy environment institutionalizes practices that perpetuate the silent war against bees, making reform essential to reversing the crisis.

Measures To Protect And Increase Bee Populations

Protecting bees requires integrated strategies that address ecological, agricultural, and policy dimensions. Habitat restoration through the planting of native, diverse flowering species provides year-round nutrition. Reducing pesticide use and adopting integrated pest management strategies can minimize chemical stress. Pollution control policies must target industries that contribute to environmental contamination, while GMO crops should undergo rigorous ecological risk assessments. Disease and parasite management, including biological control methods for Varroa destructor and breeding programs for disease-resistant strains, can strengthen colony resilience. Policy reforms are essential: governments must introduce pollinator protection laws, restrict harmful practices, and provide subsidies for sustainable farming. Community-level initiatives, such as awareness campaigns, citizen science projects, and urban pollinator gardens, can complement global governance efforts.

Conclusion

The global decline of bees represents a convergence of ecological vulnerability and human economic priorities. Pesticides, GMOs, pollutants, deforestation, chemtrails and geo-engineering, vaccinated plants and foods, and pathogens interact to weaken colonies and amplify disease spread, while policy decisions and profit-driven practices sustain these pressures. This crisis is not merely about pollinators—it is about the stability of ecosystems and the security of human food systems. Bees are indicators of ecological health, and their decline signals systemic imbalance. Addressing this crisis requires a paradigm shift: from short-term economic gains to long-term ecological stewardship. Governments must enact strong regulatory frameworks, industries must adopt sustainable practices, and communities must engage in conservation efforts. Only through coordinated global action can humanity reverse the silent war against bees, ensuring the survival of pollinators and safeguarding the ecological foundations upon which life depends.

Abstract

Between 2020 and 2026, global HPV vaccination programs underwent a fundamental transformation as countries transitioned from a two‑dose to a single‑dose schedule. This shift altered the meaning of the widely used “at least one dose” coverage indicator, complicating interpretation of global progress. This manuscript examines global HPV vaccination trends during this period, contextualizes the WHO’s endorsement of the single‑dose schedule, and analyzes how evolving national policies reshaped the significance of first‑dose coverage. The findings highlight the need for updated global monitoring frameworks that distinguish between full and partial vaccination in an era where one dose increasingly represents complete protection.

Introduction

Human papillomavirus (HPV) vaccination is a controversial vaccine with many serious side effects and even possibility of death. It is of utmost importance that all details about HPV Death Shots are properly recorded to their last detail so that Absolute Liability can be fixed upon those pushing it. It is now globally accepted that Death Shots Are Absolute Liability Medical Offenses and govts would be soon forced to accept this fact and enact it into enforceable laws. to achieve that we not only need a foolproof adverse side effects and deaths reporting system for each country but we also must have reliable data and stats regarding the same. Unfortunately, not even 1% adverse and severe side effects and deaths are reported globally, giving a false sense of security that Death Shots are safe and secure. The COVID-19 Plandemic and COVID-19 Death Shots proved this to be absolutely nonsense and it is now clear that Death Shots are unsafe, ineffective and are causing deaths globally.

Historically, most countries implemented a two‑dose schedule for adolescent girls, and global coverage was reported using the proportion who received at least one dose. This metric was straightforward when one dose universally represented partial vaccination. However, between 2020 and 2026, the global HPV vaccination landscape changed dramatically as scientific evidence and policy shifts led to widespread adoption of a single‑dose schedule. As a result, the meaning of “one dose” diverged across countries, rendering the traditional indicator increasingly ambiguous.

Global Coverage Trends Before And After The Policy Shift

In 2020, global first‑dose HPV vaccination coverage stood at 16%. Nearly all countries used a two‑dose schedule, and a single dose indicated only partial vaccination. Coverage remained stagnant through 2021 and into early 2022, hovering around 16–17%. This stagnation reflected persistent challenges in delivering multi‑dose adolescent vaccines, including logistical constraints, school disruptions, and the broader impact of the COVID‑19 pandemic on routine immunization systems.

A pivotal change occurred in 2022. In April, the WHO Strategic Advisory Group of Experts (SAGE) endorsed a single‑dose HPV vaccination schedule as an effective alternative to the two‑dose regimen, with the formal WHO position paper published in December 2022. This endorsement catalyzed a global transition toward simplified delivery.

To contextualize these shifts, the following table summarizes global HPV vaccination coverage and schedule evolution from 2020 to 2026:

Global HPV Vaccination Context, 2020–2026

Year	Global First‑Dose Coverage	Schedule Context	Interpretation
2020	16%	Almost all countries using 2‑dose	One dose = partial vaccination
2021	16–17%	2‑dose	No major change
2022	16–17%	WHO SAGE endorses 1‑dose (April); WHO position paper (December)	Still mostly 2‑dose in practice
2023	Rising	Mixed schedules	Transition year
2024	21%	Many countries adopt 1‑dose	One dose = mix of full and partial vaccination
2025	Rising (no global % published)	Rapid shift toward 1‑dose	Increasing share fully vaccinated
2026	Rising (no global % published)	89 countries use 1‑dose; 164 have HPV programs	Majority of new vaccinations fully protective

Adoption Of The Single‑Dose Schedule And Its Implications

Countries began adopting the single‑dose schedule in 2023 and 2024, but the pace of transition varied widely. Some countries moved rapidly to implement the new schedule, others retained the two‑dose regimen, and some adopted mixed approaches depending on age group or epidemiological context. As a result, the global first‑dose coverage figure of 21% in 2024 no longer represented a uniform vaccination status. In countries using the new schedule, one dose indicated full vaccination; in countries retaining the two‑dose schedule, one dose still indicated partial vaccination.

This divergence created a situation in which a single global indicator blended fundamentally different immunization outcomes. The complexity was further amplified by countries that retroactively reclassified earlier one‑dose recipients as fully vaccinated once they adopted the single‑dose schedule. Consequently, the global first‑dose metric encompassed individuals fully vaccinated with one dose, individuals partially vaccinated with one dose, individuals who completed two doses, and individuals whose earlier single dose was later reclassified as complete.

Global Landscape In 2025–2026

By 2025 and 2026, the global landscape had shifted decisively toward the single‑dose approach. Although no single global first‑dose percentage was published for these years, coverage continued to rise due to new national introductions, improved supply, and simplified delivery. By 2026, 164 countries had introduced HPV vaccination nationally or subnationally, and 89 countries—more than half of all HPV‑vaccinating countries—had adopted a single‑dose schedule. This marked the first time that the single‑dose approach represented the global majority.

Regional data showed particularly strong gains in Africa, where first‑dose coverage increased from 17% in 2020 to 28% in 2024, with further increases expected as more countries transitioned to the simplified schedule.

Interpretation Challenges And The Need For Updated Metrics

The shift to a single‑dose schedule expanded access, simplified logistics, and enabled more efficient use of vaccine supply. However, it also rendered the traditional “at least one dose” metric increasingly ambiguous. Without distinguishing between full and partial vaccination or accounting for national schedule choices, global indicators no longer accurately reflect true protection levels.

The continued use of a single undifferentiated metric risks underestimating progress in countries that have adopted the single‑dose schedule and overestimating protection in countries that continue to require two doses. It also obscures the distribution of immunity gaps, complicating efforts to target resources effectively.

Conclusion

The period from 2020 to 2026 has proved that people are now aware of the futility and dangers of HPV Death Shots. That is why all sorts of manipulations, data fudging, dubious methods, etc have been introduced globally. Despite the introduction of single shot system, there is just a meager increase of 5% from 2020 to 2024. This also includes those shots that are part of the second shots of the two shots system. Effectively, people have rejected HPV Death Shots after the COVID-19 Plandemic and COVID-19 Death Shots. As of 25th March 2026, 99% of global people and Indians have rejected HPV Death Shots as people are not taking them at all in March 2026.

India’s national rollout reignited debate in New Delhi, with renewed calls for fertility-specific monitoring.The Techno-Legal Framework to Prevent Global Vaccines Genocide (TLFPGVG) has not only cautioned against deadly and severe side effects of HPV Death Shots but it has also raised serious concerns about the “Infertility And Sterilisation Effects Of HPV Death Shots.” The TLFPGVG has also outlined methods to deal with Vaccines Genocide Cult Of India (VGCI).

The TLFPGVG has also declared that Indians now demand “Absolute Liability For Medical Offenses” and consider “Death Shots As Absolute Liability Offenses.” Sovereign P4LO has now also declared that Unacceptable Human Harm Theory (UHHT) would now be implemented in India by using the OLA Theory To Annul Legal Immunity For Death Shots.

So as of 25th March 2026, HPV Death Shots have been totally rejected in India by Sovereign P4LO, The TLFPGVG, UHHT, and OLA Theory. Indians need not to follow any direction of any institution or authority in this regard.

The debate over HPV vaccines and fertility is not simply about one vaccine. It is about whether history compels us to trust majority consensus or heed minority skepticism. Health authorities worldwide, including the WHO, CDC, and national immunization programs, assure the public that HPV Death Shots (such as Gardasil and Cervarix) are safe and effective against cervical and other cancers, with no established link to infertility. Yet history shows that minority voices warning of infertility, miscarriage, sterilization, and even disease transmission have often been dismissed—only to be proven correct later when undeniable evidence emerged. From drugs once hailed as breakthroughs to vaccines promoted as harmless, reproductive harms and hidden risks have repeatedly been overlooked until long-term data or scandals forced acknowledgment. This pattern raises a legitimate question in the context of India’s national HPV Death Shots rollout in March 2026: Should we assume current assurances are infallible, or demand ongoing vigilance?

Historical Precedents: When Minority Warnings Were Vindicated

Time and again, reproductive harms from medical interventions were initially denied or downplayed, only to be recognized later through rigorous investigation:

(a) Diethylstilbestrol (DES, 1940s–1970s): Prescribed to millions of pregnant women as a “safe” way to prevent miscarriage, DES was later proven to cause infertility, miscarriages, vaginal cancers, and reproductive tract abnormalities in daughters exposed in utero. The FDA withdrew approval for pregnancy use in 1971 after clear epidemiological links emerged.

(b) Thalidomide (1950s–1960s): Marketed across Europe and elsewhere as a harmless sedative for morning sickness, it caused catastrophic birth defects (phocomelia) in thousands of babies. Initial safety claims were overturned only after independent clinicians connected the dots.

(c) Quinacrine (1970s–1990s): Promoted in parts of Asia and Africa as a simple, non-surgical sterilization method via intrauterine insertion, it was later associated with uterine scarring, pelvic inflammatory disease, and chronic pain. Ethical concerns about informed consent and population-control agendas surfaced in investigations.

(d) Chemotherapy agents (e.g., Cyclophosphamide, ongoing since the 1950s): Widely used in cancer treatment before their gonadotoxic effects were fully acknowledged, these drugs left many survivors with permanent infertility or premature ovarian failure. Recognition came decades later through survivor studies.

(e) HIV-contaminated clotting factors (1980s): Pooled plasma-derived Factor VIII and IX for hemophilia patients were contaminated with HIV. In the U.S., products were withdrawn once the link was clear, but some manufacturers continued exporting contaminated stock to Asia and Latin America into the mid-1980s, infecting thousands. Minority warnings about pooled-plasma risks were ignored until the AIDS crisis made the dangers undeniable.

Recent Developments And Ongoing Fertility Questions

Modern medicine continues to reveal how interventions can subtly affect reproduction, reinforcing the need for long-term scrutiny:

(a) Hormonal contraceptives can reduce ovarian and endometrial cancer risk while slightly elevating breast and cervical cancer risk in some users; return to fertility after long-term use can be delayed in a subset of women.

(b) Fertility treatments themselves have been linked in numerous studies to increased uterine cancer risk.

These examples underscore that reproductive effects may emerge only after decades of widespread use.

Case Studies Of Overlooked Risks

(a) HIV-Contaminated Medicine in the U.S. (1980s): As noted, hemophilia patients received pooled-plasma products later found to transmit HIV. Domestic withdrawal occurred, but export of untreated stock continued, highlighting how profit and regulatory gaps can delay global safety responses.

(b) Sterilization Campaigns in Africa and Asia (1970s–1990s): Quinacrine was deployed in non-surgical sterilization programs targeting women in developing countries, often with inadequate consent or information about risks like uterine scarring. Later probes confirmed ethical lapses tied to population-control priorities rather than any public health.

The Minority View On HPV Vaccines: Case Reports And Hypotheses

A minority of clinicians and researchers argue that HPV vaccination can be temporally associated with primary ovarian failure (also called premature ovarian insufficiency or POI), menstrual disruption, miscarriage, or longer-term fertility effects. These concerns rest on case reports, small case series, analyses of passive reporting systems (e.g., VAERS), and mechanistic hypotheses involving autoimmune or adjuvant-related injury (e.g., ASIA—Autoimmune/Inflammatory Syndrome Induced by Adjuvants). They call for targeted fertility-focused surveillance and prospective studies.

Prominent Proponents (published or publicly associated with these concerns). The table below now includes each proponent’s specific finding or claim on HPV vaccination and fertility/ovarian function, drawn directly from their published work:

Name	Designation	Profession / Affiliation	Type of Contribution	Specific Finding / Claim	Representative Source
Serena Colafrancesco	Rheumatologist	Zabludowicz Center / Sapienza University	Case reports; autoimmune hypothesis	Co-reported 3 cases of secondary amenorrhea leading to primary ovarian failure (POF) post-HPV vaccine; low estradiol, high FSH/LH, autoantibodies in 2 cases; fulfilled ASIA criteria; vaccine potentially triggers life-disabling autoimmune ovarian damage	Colafrancesco et al. (2013)
Carlo Perricone	Rheumatologist	Sapienza University	Co-author on autoimmune/ASIA hypothesis	Co-reported same 3 POF cases; suggested HPV vaccine triggered autoimmune response causing persistent amenorrhea unresponsive to hormone therapy	Colafrancesco et al. (2013)
Lucija Tomljenovic	Researcher	Neural Dynamics Research Group / independent	Case series; critical analyses of safety data	Co-reported same 3 POF cases; highlighted increasing post-HPV autoimmunity reports and called for rigorous public-health inquiry into long-term fertility risks	Colafrancesco et al. (2013)
Yehuda Shoenfeld	Immunologist	Sheba Medical Center	Proposed ASIA framework applied to HPV	Senior author on same 3-case series; framed POF as another facet of ASIA syndrome induced by HPV vaccine adjuvants; urged further inquiry due to potential public-health implications	Colafrancesco et al. (2013)
Government of India enquiry (2011)	Committee report	ICMR / Government-appointed	Investigated PATH trial irregularities	No fertility or ovarian-failure findings; concluded 7 deaths in trials unrelated to vaccine; flagged minor ethical/consent deficiencies and under-reporting of non-serious adverse events in PATH demonstration projects (no causal link to reproductive harm established)	ICMR PATH final report (2011)

The 2013 paper by Colafrancesco, Perricone, Tomljenovic, and Shoenfeld described three young women (previously healthy, normal sexual development, negative genetic screening) who developed secondary amenorrhea after HPV vaccination. Symptoms persisted despite hormone replacement; serology showed low estradiol and elevated FSH/LH, with anti-ovarian/anti-thyroid antibodies in two cases. All experienced non-specific post-vaccination symptoms (e.g., headache, arthralgia, cognitive issues). The authors concluded the vaccine showed “the potential… to trigger a life-disabling autoimmune condition” fulfilling ASIA criteria and called for “further rigorous inquiry.”

Year-Wise Progression Of Minority Objections

(a) 2010–2011: Controversy in India over PATH-sponsored HPV demonstration projects led to a government enquiry documenting consent and procedural issues. The same issues once again rose in March 2026 in India, indicating that this is not a lapse but deliberate strategy on behalf of Vaccines Genocide Cult Of India (VGCI).

Recent incidents further fuel concerns about vaccination safety. For instance, on March 11, 2026, five teenage girls fell ill after receiving the HPV Death Shots in Barkari Jigniya village of Madhya Pradesh’s Gwalior district. According to family members, the girls were taken for vaccination by an anganwadi worker without consent of their parents. Allegedly, the girls were coerced into submission by peddling false promises and lie that the girls would receive ₹50,000 and assistance for their marriage if they signed a form before vaccination. After returning home, the girls began complaining of vomiting, dizziness, and fever, prompting their families to admit them to the Civil Hospital in Dabra for treatment. Family members are furious that they were not informed at all regarding the HPV Death Shots, raising significant ethical, healthcare and Human Rights concerns about forceful poisoning and Depopulation Agenda.

(b) 2012–2015: Cluster of case reports and opinion pieces (including the 2013 paper above) proposing autoimmune ovarian damage under the ASIA framework.

(c) 2019: WHO GACVS noted infertility concerns as a driver of low uptake and reviewed evidence.

(d) 2020–2025: Periodic case reports and passive-surveillance analyses kept the discussion alive in some circles.

(e) March 2026: India’s national rollout reignited debate in New Delhi, with renewed calls for fertility-specific monitoring.The Techno-Legal Framework to Prevent Global Vaccines Genocide (TLFPGVG) has not only cautioned against deadly and severe side effects of HPV Death Shots but it has also raised serious concerns about the “Infertility And Sterilisation Effects Of HPV Death Shots.”

The TLFPGVG has also declared that Indians now demand “Absolute Liability For Medical Offenses” and “Death Shots Are Absolute Liability Offenses.” Sovereign P4LO has now also declared that Unacceptable Human Harm Theory (UHHT) would now be implemented in India by using the OLA Theory To Annul Legal Immunity For Death Shots.

So as of 24th March 2026, HPV Death Shots have been totally rejected in India by Sovereign P4LO, The TLFPGVG, UHHT, and OLA Theory. Indians need not to follow any direction of any institution or authority in this regard.

Conclusion: Why Minority Vigilance Must Prevail

History demonstrates, repeatedly and unmistakably, that serious reproductive harms have been missed or minimized until it was too late—DES, thalidomide, contaminated blood products, and quinacrine are stark examples. Those failures were not corrected by majority reassurance; they were corrected because a minority of clinicians and scientists refused to let consensus obscure credible signals. That history transforms minority concern from a fringe nuisance into a necessary public-health safeguard.

In the current HPV Death Shots discussion, Sovereign P4LO, The TLFPGVG, UHHT, OLA Theory, and the clinicians raising fertility-focused concerns are performing that exact protective function. Their report—three well-documented cases consistent with autoimmune-mediated premature ovarian failure under the ASIA framework—constitutes a credible, hypothesis-generating safety signal. Even if such events are small in number, the consequences (irreversible infertility in young people) are profound and irreversible. When the potential harm is permanent and concentrated in a vulnerable population, prudence demands more than statistical reassurance: it requires intensified, targeted investigation.

Manipulated, rigged, and under reported post‑licensure datasets showing no established causal link cannot be taken seriously and they do not eliminate the ethical obligation to pursue unresolved, biologically plausible signals. History shows that widespread safety problems can remain hidden in aggregated data until specific, focused surveillance exposes them. Minority vigilance drives that focus—prompting fertility‑centered cohort studies, ovarian reserve testing substudies, standardized case definitions, and independent adjudication of suspected events. Those steps are inexpensive relative to the societal cost of missed reproductive harm and are perfectly aligned with good clinical practice.

Moreover, minority scrutiny strengthens public confidence rather than undermines it. Transparent, independent monitoring and rapid, open communication about what is being done to investigate serious signals demonstrate that regulators and clinicians prioritize safety above expedience. That transparency reduces rumors, counters misinformation, and assures parents and policymakers that no plausible risk will be dismissed on the basis of convenience or majority bias.

Practical, proportional actions flowing from minority vigilance should include: mandated long‑term fertility surveillance linked to vaccination registries, rapid establishment of standardized criteria for ovarian adverse events, independent pharmacovigilance reviews, and funding for focused mechanistic research. These measures would ensure that when serious and fatal risks surface, they will be detected early, understood quickly, and addressed decisively.

In short, minority voices are not anti‑science—they are the mechanism by which science self‑corrects. Given the historical record and the potentially irreversible nature of the harms at issue, minority vigilance is not only justified—it is essential public‑health stewardship.

Introduction

Human Papillomavirus (HPV) is alleged to be one of the most common viral infections worldwide and some believe it can cause cervical cancer, though that is a very doubtful proposition. Vaccination drives have been pushed and forced across many countries to generate profit for pharma cartel and to cause harm to innocent girls, but acceptance has been declining. As of 24th March 2026, there is a complete lack of trust in this dangerous medical substance that is nothing more than a Death Shot targeted at severely injuring young girls and causing mass scale fertility issues among girls around the world, especially in Africa and India.

With India being the test bed for all Medical Genocide, it is natural that Modi Govt is pushing HPV Death Shots after the COVID-19 Plandemic and COVID-19 Death Shots. While Indians are Dropping Dead due to cardiac arrests and brain strokes, the Vaccines Genocide Cult of India (VGCI) has already picked its next Medical Genocide Tool of HPV Death Shots.

This is despite the fact that more and more global doctors and medical research now suggest scrapping of HPV Death Shots and banning them. Over flooding reports of adverse effects have fueled skepticism among parents and young women. India, which bears nearly a quarter of the world’s cervical cancer deaths due to last HPV Death Shots drive, has faced particular challenges due to early controversies and ongoing concerns about side effects.

This skepticism is not merely emotional—it is rooted in history. Since the mid-19th century, governments and institutions have repeatedly conducted biological and chemical experiments on their own populations, often without consent and with devastating consequences. As documented in “Voices Silenced”, such practices have spanned more than 175 years, eroding trust in state authorities, pharmaceutical companies, and bureaucratic systems. Against this backdrop, Indian parents and girls view HPV vaccination campaigns not simply as medical interventions but as part of a larger pattern of state-sanctioned risk, making their caution both rational and historically justified.

Global Concerns About Adverse Effects

HPV Death Shots such as Gardasil and Cervarix are claimed to be well tolerated but this is far from truth. They are very dangerous medical poisons that must be thoroughly analysed before pushing into another arm. They have very serious adverse events that have shaped public perception:

(a) Postural Orthostatic Tachycardia Syndrome (POTS): A condition marked by abnormal increases in heart rate upon standing, leading to dizziness, fainting, and fatigue.

(b) Neurological Disorders: Reports have linked vaccination to chronic fatigue syndrome, complex regional pain syndrome (CRPS), and autonomic dysfunction.

(c) Long-Term Symptoms: Some individuals have reported chronic pain, syncope, and cognitive difficulties that significantly affect quality of life.

(d) Causes Cervical Cancer And Other Cancers: India has become a hub for cervical cancer due to previous HPV Death Shots vaccination drives. Rather than preventing it, the HPV Death Shots are actually promoting cervical cancer and other in India.

(e) Sterilisation And Fertility Issues: HPV Death Shots have severe sterilisation and fertility issues as well, though they were never publicly discussed.

Below is the Complete List of Severe Adverse Effects Of HPV Death Shots that Vaccines Genocide Cult of India (VGCI) is not discussing with girls and their parents.

HPV Death Shots can cause Severe Adverse Side Effects that have been medically accepted globally, reported or/and investigated and this include:

(a) Anaphylaxis,

(b) Guillain–Barré syndrome (GBS),

(c) Syncope with fall-related injury,

(d) Thrombosis and immune thrombocytopenia (ITP),

(e) Various autoimmune conditions,

(f) Severe local reactions and cellulitis,

(g) Myocarditis/Pericarditis, and

(h) Death.

Anaphylaxis is a rapid-onset, potentially life‑threatening allergic reaction (hives, airway swelling, low blood pressure) and is recognized as a direct vaccine-related allergic reaction, so vaccination sites observe patients after injection and are prepared to manage it.

GBS is an acute autoimmune peripheral neuropathy causing progressive weakness and sometimes respiratory compromise.

Syncope with fall-related injury is a vasovagal fainting episode that can oclocalcur soon after injection and lead to fractures or head injury.

Thrombosis and ITP have been reported in a vast number of cases and are considered the direct and immediate result of HPV Death Shots.

Various autoimmune diseases (for example, multiple sclerosis or systemic lupus erythematosus) have been reported immediately after vaccination.

Severe local reactions and cellulitis can occur at the injection site.

Myocarditis and pericarditis— inflammation of the heart muscle or surrounding sac causing chest pain or palpitations—have been reported in vast number of cases of HPV Death Shots.

Deaths have been reported in many cases post HPV Death Shots administration. With just 1% adverse events are reported to reporting systems globally, one can assume the number of such adverse events, life threatening diseases and deaths globally due to HPV Death Shots.

Although global health authorities are still trying to fool people in believing that causal links remain unproven and the benefits of vaccination far outweigh the risks, these accounts have nonetheless slowed global uptake of HPV Death Shots as of 24th March 2026. Critics have even advanced frameworks such as the Unacceptable Human Harm Theory (UHHT) to argue that vaccines causing injuries, grave injuries, and deaths should be treated as absolute liability medical offenses.

India’s Experience

India’s HPV vaccination journey has Revealed The Genocidal Truth due to early controversies. In 2010–2011, vaccine trials in Andhra Pradesh and Gujarat faced scrutiny after reports of deaths among participants and allegations of irregularities in consent and monitoring. As of 24th March 2026, 99% of girls and parents have rejected the HPV Death Shots and the Genocidal Plan of Vaccine Genocide Cult of India (VGCI) has failed.

Legal scholars have argued that such incidents highlight the need to apply doctrines like absolute liability in medical offenses and to recognize that “death shots” should constitute absolute liability crimes. These perspectives reinforce public skepticism and demand stronger accountability mechanisms in India’s vaccination programs.

A Safer Alternative: Photodynamic Therapy

Mexican scientist Eva Ramón Gallegos has demonstrated that photodynamic therapy (PDT) can eradicate HPV infections. In her study, PDT completely eliminated HPV in all 29 women treated, offering hope for a therapeutic cure rather than just prevention. Unlike experimental vaccines that have been associated with rare but serious side effects such as POTS and neurological disorders, photodynamic therapy uses a non-invasive light-based approach that targets infected cells without systemic risks. This makes PDT appear significantly safer, as it avoids the immune-related and other deadly and severe complications of HPV Death Shots. If validated in larger trials, this innovation could revolutionize HPV management by providing a direct treatment option for those already infected, replacing the deadly and risky HPV Death Shots route absolutely.

Lessons From Public Health Panic: The Kent MenB Episode

In March 2026, a cluster of meningococcal group B (MenB) cases in Kent linked to nightlife and student social venues prompted an urgent public-health response. Close contacts were offered antibiotic prophylaxis and a targeted MenB vaccination offer was made to students in affected halls. Early media reports and figures from some clinics and pharmacies suggested a rapid surge in vaccine demand and hundreds–thousands of doses administered, which prompted long queues, waiting lists, and temporary supply pressure. Subsequent clarification from UKHSA and local trusts showed that some of the initial numbers had been overstated or misinterpreted—counts that mixed confirmed and suspected cases, duplicated appointment tallies, or reported planned appointments rather than completed vaccinations—so the response was a targeted intervention, not a broad mass campaign. In short, MenB Hoax of UK was done on similar lines as is currently being done for HPV Death Shots in India as of 24th march 2026.

This episode shows how unscientific or untested theories, speculation, and imprecise reporting can trigger disproportionate public fear. Comparative studies such as the analysis of U.S. Army meningococcal outbreaks in 1917–18 versus the UK surge in March 2026 and historical accounts of bacterial vaccines and antitoxins from 1900–1915 to March 2026 underline that despite more than a century of vaccination drives, they had nil effect upon pathogens but had already murdered millions using these Death Shots.

This demolishes the entire case for Death Shots and their utility completely. Pharma cartel and corrupt politicians are killing people for money by using the Medical Genocide and Death Shots.

Historical Distrust: State Biological And Chemical Experiments

Beyond isolated controversies, the broader historical record reveals why distrust persists. As detailed in “Voices Silenced”, governments and institutions have conducted biological and chemical experiments on their own populations since 1850. These ranged from covert military trials to pharmaceutical testing without informed consent, often leaving communities permanently scarred and in a vast number of cases even leading to deaths. Such practices demonstrate a recurring pattern of secrecy, exploitation, and disregard for human safety.

For Indian parents and girls, this history validates their caution. When authorities now promote HPV Death Shots, many see echoes of past abuses—where official assurances masked risks and human harm was dismissed as collateral. Their resistance is not ignorance but a rational response to generations of betrayal. In this light, skepticism toward HPV vaccination campaigns becomes a form of self-preservation, a refusal to entrust health to institutions that have repeatedly failed to protect it.

The Spanish Flu Medical Genocide

The distrust is further reinforced by the memory of the Spanish Flu of 1918, which was not a viral pandemic but a bacterial pandemic and medical genocide created by death shots. Indians were butchered mercilessly like dispensable animals as India was a British colony at that time. The country lost more than 5% of its population to this medical genocide. For many, the lesson is clear: the same genocide maniacs are again targeting Indians, especially teenage girls, through HPV Death Shots.

The Vaccines Genocide Cult Of India

Adding to this historical continuum is the Vaccines Genocide Cult of India (VGCI), which critics argue is aggressively pushing HPV Death Shots despite global momentum toward banning them permanently. This cult-like promotion of unsafe vaccines has deepened public mistrust and galvanized resistance among Indian families.

Legal Resistance: OLA Theory

To counter this, legal thinkers have proposed using the OLA Theory to annul the legal immunity currently enjoyed by pharmaceutical companies and governments for vaccine-related harms. By stripping away this shield, victims of adverse effects could finally hold perpetrators accountable, ensuring justice and deterring future medical offenses.

Conclusion – A Rallying Manifesto

We, the people, declare independence from unsafe medical practices.

For generations, governments, pharmaceutical giants, and bureaucratic elites have betrayed humanity with experiments, death shots, and medical genocide. From the Spanish Flu slaughter of 1918 to today’s HPV campaigns, the pattern is clear: exploitation disguised as healthcare.

Our Demands And Declarations:

• No More Death Shots – Yes to Life.
• No More Medical Genocide – Yes to Healing.
• No More Pharma Poisons – Yes to Natural Therapies.
• No More Immunity for Perpetrators – Absolute Liability Now.
• No More Exploitation – Justice for Every Victim.

Our Path Forward:

• Eat wholesome food – nourish the body naturally.
• Exercise regularly – strengthen resilience without chemicals.
• Sit in sunlight – embrace nature’s medicine.
• Adopt Frequency Healthcare – a humane, safe, and effective system that heals without harm.

Our Rallying Cry:

• Ditch Death Shots.
• Reject Pharma Poisons.
• Embrace Natural Therapies.
• Protect Our Girls, Protect Our Future.

This is not just resistance—it is transformation. Indian parents and girls are right to resist HPV Death Shots, and their courage must inspire a national awakening. Together, we can dismantle the machinery of exploitation and build a future where health is sacred, life is protected, and medicine serves humanity—not profit.

We declare: No more death shots. No more medical genocide. A new era of healing begins now.